ATE442356T1 - 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung - Google Patents
1-essigsäureindolderivate mit pgd2- antagonistischer wirkungInfo
- Publication number
- ATE442356T1 ATE442356T1 AT06726357T AT06726357T ATE442356T1 AT E442356 T1 ATE442356 T1 AT E442356T1 AT 06726357 T AT06726357 T AT 06726357T AT 06726357 T AT06726357 T AT 06726357T AT E442356 T1 ATE442356 T1 AT E442356T1
- Authority
- AT
- Austria
- Prior art keywords
- acetic acid
- antagonistic effect
- pgd2
- alkyl
- indol derivatives
- Prior art date
Links
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title abstract 2
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 title abstract 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 title abstract 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505048.9A GB0505048D0 (en) | 2005-03-11 | 2005-03-11 | Compounds with PGD antagonist activity |
| PCT/GB2006/000851 WO2006095183A1 (en) | 2005-03-11 | 2006-03-10 | 1-acetic acid-indole derivatives with pgd2 antagonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE442356T1 true ATE442356T1 (de) | 2009-09-15 |
Family
ID=34508918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06726357T ATE442356T1 (de) | 2005-03-11 | 2006-03-10 | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8044088B2 (de) |
| EP (1) | EP1856045B1 (de) |
| JP (1) | JP2008532990A (de) |
| KR (1) | KR20070116633A (de) |
| CN (1) | CN101166721A (de) |
| AT (1) | ATE442356T1 (de) |
| AU (1) | AU2006221784A1 (de) |
| BR (1) | BRPI0608732A2 (de) |
| CA (1) | CA2601980A1 (de) |
| CY (1) | CY1109532T1 (de) |
| DE (1) | DE602006009080D1 (de) |
| DK (1) | DK1856045T3 (de) |
| ES (1) | ES2333161T3 (de) |
| GB (1) | GB0505048D0 (de) |
| HR (1) | HRP20090654T1 (de) |
| IL (1) | IL185844A0 (de) |
| MX (1) | MX2007011091A (de) |
| NO (1) | NO20074641L (de) |
| NZ (1) | NZ561747A (de) |
| PL (1) | PL1856045T3 (de) |
| PT (1) | PT1856045E (de) |
| RS (1) | RS51016B (de) |
| RU (1) | RU2007134456A (de) |
| SI (1) | SI1856045T1 (de) |
| WO (1) | WO2006095183A1 (de) |
| ZA (1) | ZA200708159B (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| EP2037967B1 (de) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 rezeptor antagonisten zur behandlung androgener alopezie |
| PT2046740E (pt) | 2006-07-22 | 2012-08-28 | Oxagen Ltd | Compostos com atividade antagonista do crth2 |
| KR101411820B1 (ko) | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체 |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| CA2707785C (en) * | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| PT2250161E (pt) * | 2008-01-18 | 2014-01-21 | Atopix Therapeutics Ltd | Compostos tendo atividade antagonista de crth2 |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| EP2492267B1 (de) * | 2009-02-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Indolederivate als CRTH2 receptor Antagonisten in Kombination mit einer zweiten Wirksubstanz |
| WO2011117798A1 (en) | 2010-03-22 | 2011-09-29 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| MY165623A (en) | 2011-04-14 | 2018-04-18 | Idorsia Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| PL2781508T3 (pl) * | 2011-11-17 | 2019-06-28 | Kbp Biosciences Co., Ltd. | Związki pierścieniowe o układzie skondensowanych pierścieni zawierające azot do zastosowania jako antagonisty CRTH2 |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| ES2690782T3 (es) | 2012-10-24 | 2018-11-22 | Nyu Winthrop Hospital | Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro |
| KR102116978B1 (ko) | 2013-10-07 | 2020-05-29 | 삼성전자 주식회사 | 그래핀 소자 및 그 제조 방법 |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| HRP20181555T1 (hr) | 2014-03-17 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2 |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| ES2991300T3 (es) | 2015-02-13 | 2024-12-03 | Inserm Institut Nat De La Sante Et De Larecherche Medicale | Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico |
| MX2018001217A (es) | 2015-07-30 | 2018-09-12 | Univ Pennsylvania | Alelos polimorficos de nucleotidos individuales del gen humano dp-2 para la deteccion de la susceptibilidad a la inhibicion del crecimiento del cabello por pgd2. |
| PL3350179T3 (pl) | 2015-09-15 | 2021-08-02 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
| CN111094988A (zh) | 2017-09-13 | 2020-05-01 | 普罗根尼蒂公司 | 先兆子痫生物标志物及相关系统和方法 |
| CN109180691B (zh) * | 2018-08-24 | 2020-07-10 | 武汉大学 | 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法 |
| EP4070113A4 (de) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | Beurteilung von präeklampsie unter verwendung von tests für freien und dissoziierten plazentalen wachstumsfaktor |
| CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
| CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
| WO2024192765A1 (en) * | 2023-03-23 | 2024-09-26 | Brown University | First in class use of the crth2 antagonist in treating neuromyelitis optica spectrum disorder (nmosd) and relevant autoimmune cns disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| WO1999050268A2 (en) * | 1998-03-31 | 1999-10-07 | The Institutes For Pharmaceutical Discovery, Inc. | Substituted indolealkanoic acids |
| JP4484108B2 (ja) * | 2002-05-16 | 2010-06-16 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗作用を有する化合物 |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| PT2046740E (pt) * | 2006-07-22 | 2012-08-28 | Oxagen Ltd | Compostos com atividade antagonista do crth2 |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| WO2009093026A1 (en) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
-
2005
- 2005-03-11 GB GBGB0505048.9A patent/GB0505048D0/en not_active Ceased
-
2006
- 2006-03-10 RU RU2007134456/04A patent/RU2007134456A/ru not_active Application Discontinuation
- 2006-03-10 DE DE602006009080T patent/DE602006009080D1/de not_active Expired - Lifetime
- 2006-03-10 US US11/908,401 patent/US8044088B2/en not_active Expired - Fee Related
- 2006-03-10 PT PT06726357T patent/PT1856045E/pt unknown
- 2006-03-10 SI SI200630491T patent/SI1856045T1/sl unknown
- 2006-03-10 BR BRPI0608732A patent/BRPI0608732A2/pt not_active IP Right Cessation
- 2006-03-10 DK DK06726357T patent/DK1856045T3/da active
- 2006-03-10 AU AU2006221784A patent/AU2006221784A1/en not_active Withdrawn
- 2006-03-10 CA CA002601980A patent/CA2601980A1/en not_active Abandoned
- 2006-03-10 JP JP2008500270A patent/JP2008532990A/ja active Pending
- 2006-03-10 RS RSP-2009/0534A patent/RS51016B/sr unknown
- 2006-03-10 EP EP06726357A patent/EP1856045B1/de not_active Expired - Lifetime
- 2006-03-10 CN CNA2006800139287A patent/CN101166721A/zh active Pending
- 2006-03-10 AT AT06726357T patent/ATE442356T1/de active
- 2006-03-10 KR KR1020077023379A patent/KR20070116633A/ko not_active Withdrawn
- 2006-03-10 MX MX2007011091A patent/MX2007011091A/es active IP Right Grant
- 2006-03-10 WO PCT/GB2006/000851 patent/WO2006095183A1/en not_active Ceased
- 2006-03-10 NZ NZ561747A patent/NZ561747A/xx not_active IP Right Cessation
- 2006-03-10 ES ES06726357T patent/ES2333161T3/es not_active Expired - Lifetime
- 2006-03-10 HR HR20090654T patent/HRP20090654T1/hr unknown
- 2006-03-10 PL PL06726357T patent/PL1856045T3/pl unknown
-
2007
- 2007-09-10 IL IL185844A patent/IL185844A0/en unknown
- 2007-09-12 NO NO20074641A patent/NO20074641L/no not_active Application Discontinuation
- 2007-09-21 ZA ZA200708159A patent/ZA200708159B/xx unknown
-
2009
- 2009-12-08 CY CY20091101280T patent/CY1109532T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2333161T3 (es) | 2010-02-17 |
| GB0505048D0 (en) | 2005-04-20 |
| SI1856045T1 (sl) | 2010-01-29 |
| DE602006009080D1 (de) | 2009-10-22 |
| AU2006221784A1 (en) | 2006-09-14 |
| BRPI0608732A2 (pt) | 2016-11-08 |
| HRP20090654T1 (hr) | 2010-01-31 |
| CN101166721A (zh) | 2008-04-23 |
| ZA200708159B (en) | 2009-11-25 |
| NO20074641L (no) | 2007-11-01 |
| DK1856045T3 (da) | 2010-01-04 |
| PL1856045T3 (pl) | 2010-02-26 |
| MX2007011091A (es) | 2007-11-22 |
| KR20070116633A (ko) | 2007-12-10 |
| JP2008532990A (ja) | 2008-08-21 |
| PT1856045E (pt) | 2009-12-09 |
| US20100330077A1 (en) | 2010-12-30 |
| WO2006095183A1 (en) | 2006-09-14 |
| IL185844A0 (en) | 2008-01-06 |
| RU2007134456A (ru) | 2009-04-20 |
| CY1109532T1 (el) | 2014-08-13 |
| EP1856045B1 (de) | 2009-09-09 |
| HK1109628A1 (en) | 2008-06-13 |
| US8044088B2 (en) | 2011-10-25 |
| CA2601980A1 (en) | 2006-09-14 |
| RS51016B (sr) | 2010-10-31 |
| NZ561747A (en) | 2010-03-26 |
| EP1856045A1 (de) | 2007-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE442356T1 (de) | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| NO20080738L (no) | Fremgangsmater for neurobeskyttelse | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| CY1111295T1 (el) | Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2 | |
| GB0510584D0 (en) | Organic compounds | |
| CY1109883T1 (el) | Υδατικα συγκεντρωματα δραστικων ουσιων με ζιζανιοκτονα δραση | |
| NO20051051L (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler | |
| NO20075734L (no) | Tiofenforbindelser og trombopoietin reseptoractivatorer | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| RU2010115337A (ru) | Трициклические гетероциклические производные | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
| EA201070813A1 (ru) | Производные n-гетероциклоимидазо[1,2-а]пиридин-2-карбоксамидов, их получение и применение в терапии | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| UA97957C2 (ru) | 2-{5-фтор-2-метил-3-[2-(фенилсульфонил)бензил]-1н-индол-1-ил}уксусная кислота и ее производные, их применение для лечения заболеваний, опосредствованных действием pgd2 на рецептор crth2 | |
| EA200700997A1 (ru) | 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ | |
| NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler | |
| NO20071230L (no) | Oksazolidinoner inneholdende oksindoler som antibakterielle midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1856045 Country of ref document: EP |